SCHEMBL378776

SCHEMBL378776

Cc1noc(-c2ccc(C(=O)N3CCC(C(=O)N[C@@H](C)C4CCCCC4)(c4ccc(F)cc4)CC3)cc2)n1

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TACR3 P29371 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
IDO1 P14902 1/20 0.40
GRM5 P41594 3/20 0.39
CLPP Q16740 1/20 0.39
OPRK1 P41145 1/20 0.38
EPHX2 P34913 1/20 0.38
IDH1 O75874 1/20 0.38
F11 P03951 1/20 0.38
P2RX3 P56373 1/20 0.37
GPR119 Q8TDV5 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
MAPK1 P28482 1/20 0.36
KCNH2 Q12809 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL378032 0.92 TSHR (0.41) OPRK1F11P2RX3GPR119
SCHEMBL13102753 0.88 EPHX2 (0.46) EPHX2MEN1KMT2AMAPK1
SCHEMBL378760 0.88 EPHX2 (0.46) EPHX2MEN1KMT2AMAPK1
SCHEMBL379355 0.86 TACR3 (0.41) TACR3CYP1A2CYP2C9CYP2C19IDO1
SCHEMBL378777 0.86 TACR3 (0.40) TACR3CYP1A2CYP2C9CYP2C19IDO1
SCHEMBL13092367 0.85 TACR3 (0.40) TACR3CYP1A2CYP2C9CYP2C19IDO1
SCHEMBL13102356 0.84 TACR3 (0.40) TACR3CYP1A2CYP2C9CYP2C19IDO1
SCHEMBL13092251 0.84 BDKRB1 (0.40) TACR3CYP1A2CYP2C9CYP2C19IDO1
SCHEMBL13092448 0.83 IDO1 (0.39) TACR3CYP1A2CYP2C9CYP2C19IDO1
SCHEMBL13092467 0.83 CTSL (0.42) TACR3CYP1A2CYP2C9CYP2C19IDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2408745-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS F. Hoffmann-La Roche AG (CH) 2012-01-25 EP claimed
US-8324250-B2 Piperidine derivatives as NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-12-04 US disclosed
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2010-10-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HTR3A, OPRL1, OPRK1 TACR3 41/4885CYP1A2 1366/4885CYP2C9 2094/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.